Work

The addition of Herceptin (humanized anti-HER2 antibody) to first-line chemotherapy for HER2-overexpressing metastatic breast cancer (HER2+ MBC) markedly increases anti-cancer activity: A randomized, multinational controlled phase II trial.

Year: 1998
Type: article
Language: English
Subfield: Oncology
Field: Medicine
Open Access status: closed
OpenAlex ID: W2344444710
FWCI: 42.19
Cites:
Cited by: 347
Related to: 9